Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
Trial Details
- NCT ID
- NCT07864701
- Phase
- PHASE1 / PHASE2
- Sponsor
- Chengdu Anticancer Bioscience, Ltd.
- Status
- RECRUITING
- Cancer Type
- Non-Hodgkin Lymphoma Lymphoma
- Interventions
- Locations (sample)
- Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
- Able to fully understand the study requirements, voluntarily agree to participate in the study, and provide written informed consent.
- Male or female participants aged 18 to 75 years, inclusive.
- Histologically or cytologically confirmed malignant tumor. Participants with solid tumors must have unresectable locally advanced or metastatic dis…
- Phase Ia dose-escalation stage: Solid tumors, including but not limited to gastric cancer, colorectal cancer, non-small cell lung cancer, hepatocel…
For full eligibility, visit ClinicalTrials.gov.